Top line data from VISION will be presented at the ASCO Plenary...

Top line data from VISION will be presented at the ASCO Plenary session on 7 June.

Even though WARMTH determined that median survival of 11.6 months was achieved in their retrospective analysis of 319 patients treated with Lu-PSMA monotherapy, I expect VISION survival to be better:

• VISION patients were allowed to use other drugs at the same time as Lu-PSMA
• The patients in VISION need not have exhausted all standard treatment options
• The standard of patient care may have improved since WARMTH

My educated guess is that mOS in VISION will be about 14 months.  Based on this figure, the LuPIN result of 19.7 months would be 40.714286% better than VISION.  Whether that would be good enough to interest Novartis or vrs37 remains to be seen.